IVERIC bio, Inc. (ISEE): Price and Financial Metrics


IVERIC bio, Inc. (ISEE)

Today's Latest Price: $4.43 USD

0.14 (3.26%)

Updated Aug 7 4:00pm

Add ISEE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

ISEE Daily Price Range
ISEE 52-Week Price Range

ISEE Stock Price Chart Technical Analysis Charts


ISEE Price/Volume Stats

Current price $4.43 52-week high $8.97
Prev. close $4.29 52-week low $0.91
Day low $4.27 Volume 555,500
Day high $4.44 Avg. volume 748,405
50-day MA $4.65 Dividend yield N/A
200-day MA $4.80 Market Cap 227.41M

IVERIC bio, Inc. (ISEE) Company Bio


IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.





ISEE Latest News Stream


Event/Time News Detail
Loading, please wait...

ISEE Latest Social Stream


Loading social stream, please wait...

View Full ISEE Social Stream

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC bio Inc that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020

IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.

Yahoo | July 29, 2020

Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 17, 2020

IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors

IVERIC bio announced the election of Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors, effective as of July 15, 2020.

Yahoo | July 16, 2020

Moving Average Crossover Alert: IVERIC bio

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Yahoo | July 3, 2020

Iveric bio launches second pivotal study of Zimura in eye disorder

The first patient has been dosed in a second pivotal clinical trial, Phase 3 GATHER2, evaluating IVERIC bio's (ISEE) Zimura (avacincaptad pegol), a complement C5 inhibitor, in patients with geographic atrophy ((GA)) secondary to age-related macular degeneration.The primary endpoint of the 400-subject study is the mean rate of change in GA...

Seeking Alpha | June 30, 2020

Read More 'ISEE' Stories Here

ISEE Price Returns

1-mo -7.90%
3-mo 9.11%
6-mo -36.89%
1-year 275.42%
3-year 66.54%
5-year -91.84%
YTD -48.37%
2019 615.00%
2018 -61.54%
2017 -35.40%
2016 -93.85%
2015 75.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7701 seconds.